Efficacy Outcomes of Repotrectinib in Patients with NTRK-positive Solid Tumours By Ogkologos - February 10, 2026 300 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TRIDENT-1 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR How My Advanced Colorectal Cancer Diagnosis Led Me to Patient Advocacy March 3, 2021 Bladder Cancer Trial Finds Extended Lymph Node Surgery Doesn’t Improve Survival November 6, 2024 COVID-19 in people with cancer – what we know so far December 4, 2020 What to Know About 3 Common Misconceptions Around Food and Cancer... April 25, 2023 Load more HOT NEWS Second Interim Analysis Shows OS Improvement with Adjuvant Olaparib for Germline... 20 years of Cancer Research UK: Celebrating our research nurses The award-winning researcher behind next generation sequencing Lorlatinib in First-Line Treatment of Patients with Advanced ALK-Positive NSCLC With...
